Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P03999

UPID:
OPSB_HUMAN

ALTERNATIVE NAMES:
Blue cone photoreceptor pigment; Blue-sensitive opsin

ALTERNATIVE UPACC:
P03999; Q13877

BACKGROUND:
Short-wave-sensitive opsin 1, identified by its alternative names Blue cone photoreceptor pigment and Blue-sensitive opsin, is crucial for color vision, specifically in detecting blue light. It forms part of the visual pigments, binding to cis-retinal to mediate vision. Beyond its role in vision, it is vital for the structural integrity of cone outer segments in the ventral retina and plays a role in the distribution of retinal membrane proteins, possibly aiding in dim light conditions.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in Tritan color blindness, a condition marked by a deficiency in blue spectral sensitivity, Short-wave-sensitive opsin 1 presents a significant target for research into color vision deficiencies. Exploring the function and mechanisms of Short-wave-sensitive opsin 1 could lead to innovative treatments for improving or restoring color vision.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.